Use

Guardant360 CDx is an FDA‐approved liquid biopsy test that performs comprehensive genomic profiling using circulating tumor cell‐free DNA (cfDNA) from a blood sample. It identifies somatic mutations across a broad panel of cancer‐related genes to guide selection of targeted therapies, including companion diagnostic indications: KRAS G12C for LUMAKRAS (sotorasib), ERBB2 activating mutations for ENHERTU (fam‑trastuzumab deruxtecan‑nxki), ESR1 missense mutations for ORSERDU (elacestrant), and EGFR alterations for TAGRISSO (osimertinib), RYBREVANT (amivantamab), as well as MSI‐High status for immunotherapy eligibility. The test delivers results within approximately 7 calendar days, offering a less invasive and faster alternative to tissue biopsy for oncologic decision‑making.